Stay updated with breaking news from Bausch Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Revenues of $2.046 billion, down 3% reported, up 2% organic basisThird quarter sales improved sequentially, notably Salix, International, and SoltaSuccessful debt exchange offer reduces debt by $2.5 billionCompany
/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2022...
Bausch Health’s second leg down in 2022 is a disappointment for shareholders. Read why uncertainty will continue to weigh on BHC stock.
Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.
Learn everything about Bausch + Lomb and its parent company, Bausch Health Companies, ahead of its IPO on the New York Stock Exchange and Toronto Stock Exchange.